A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Anti Merkel Cell Panel
MessageSample needs to be shipped frozen to Quest as miscellaneous.
Sent to University of Washington Medicine.
Test code AMERK
Sent to University of Washington Medicine.
Test code AMERK
Test Code
AMERK (UWM)
Alias/See Also
AMERK
CPT Codes
0058U
Includes
All samples include testing for antibodies to the Merkel Cell Carcinoma (MCC) oncoprotein. In addition, screening for the Merkel cell polyomavirus VP1 capsid antibody is done once, on the first sample ordered for AMERK testing (AMERK2) and billed separately. The VP1 capsid antibody test is reflexively added to the order by the laboratory.
Preferred Specimen
Red top
or SST
Must centrifuge and separate serum within 4 hours of collection.
or SST
Must centrifuge and separate serum within 4 hours of collection.
Minimum Volume
2mL serum
Instructions
Must centrifuge and separate serum within 4 hours of collection.
Transport Temperature
Frozen
Specimen Stability
Room temp: 7 days
Frozen: Long Term
Frozen: Long Term
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Sample not labeled with complete first and last name and date of birth.
Lipemia may increase results 15-20%
Lipemia may increase results 15-20%
Methodology
Laboratory developed Luminex paramagnetic bead, multiplex assay
Setup Schedule
Set up on Mondays.
Report Available
3-4 weeks
Limitations
Screening for the Merkel cell polyomavirus VP1 capsid antibody is done once, on the first sample ordered for AMERK testing (and billed separately). This assay is used to screen Merkel Cell Carcinoma (MCC) patients for current or prior infection with the Merkel cell polyomavirus. Patients who lack these antibodies should not be monitored with additional AMERK testing because they do not make antibodies to the viral oncoprotein and should be monitored by other means. VP1 capsid antibodies are not an indicator of disease activity.
Clinical Significance
SmT oncoprotein antibodies are present in the blood of 50% of patients when they have clinically detectable Merkel Cell Carcinoma (MCC). In patients who make oncoprotein antibodies, titers are expected to decrease significantly within 3 months of successful treatment of MCC. Changes in oncoprotein titers of less than 25% may not be biologically significant. A significant rise in titer or stabilization above 2000 STU may be associated with persistent or recurrent MCC.
Performing Laboratory
UW Medicine
Department of Laboratory Medicine
University of Washington Medical Center
1959 NE Pacific St
Seattle, WA 98195
206-520-4600
Last Updated: December 27, 2023